Alnylam: 2Q Earnings Snapshot

August 2, 2018

CAMBRIDGE, Mass. (AP) _ Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported a loss of $163.6 million in its second quarter.

The Cambridge, Massachusetts-based company said it had a loss of $1.63 per share. Losses, adjusted for one-time gains and costs, came to $1.61 per share.

The results fell short of Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of $1.54 per share.

The RNA interference drug developer posted revenue of $29.9 million in the period, which beat Street forecasts. Five analysts surveyed by Zacks expected $19.9 million.

Alnylam shares have decreased 26 percent since the beginning of the year. The stock has risen 16 percent in the last 12 months.


This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on ALNY at https://www.zacks.com/ap/ALNY

Update hourly